Hematological malignancies
Conditions
Interventions
In the case group, additional blood samples will be taken during routine blood collection for antibody titer measurement.
In the control group, a new blood sample will be drawn for antibody titer meas
Sponsors
Kameda Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The case group consists of 1) those who are attending or hospitalized in the Department of Hematology/Oncology of our hospital, 2) those who have completed two doses of regular mRNA vaccination by December 1, 2021, and 3) those who have given written consent by themselves or a substitute who fully understands this study. The control group consisted of 1) those who had completed two doses of regular mRNA vaccination by December 1, 2021, and 2) those who had given written consent by themselves or a substitute who fully understood this study. Translated with www.DeepL.com/Translator (free version)
Exclusion criteria
Exclusion criteria: 1) If the researcher cannot obtain written consent for participation in the research from an individual or a substitute, 2) If an individual is under 20 years of age, or 3) If the principal investigator and subcontractors determine that an individual is ineligible for the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody titer measured at each time point in the case group | — |
Countries
Japan
Contacts
Public ContactDaisuke Ikeda
Kameda Medical Center Division of Hematology/Oncology
Outcome results
None listed